PubMed COVID-19 Clinical Care

CONCLUSION: Two BNT162b messenger RNA vaccine doses provided moderate protection against symptomatic COVID-19 during the Omicron variant period. A time-dependent decrease in VE was noted after the second dose; thus, a booster dose 3 months after the

Background: This study aimed to determine the real-world safety and effectiveness of remdesivir in hospitalized adult COVID-19 patients with moderate-to-critical disease in Indonesia. Methods: A multicenter, retrospective cohort study was conducted

The discovery of X-ray in 1895 and the first X-ray image of Mrs. Röntgen's hand opened up a new era of radiology and the research of medical imaging. The evolution of traditional medical imaging has been lasting for over 100 years, serving the

Investigations on spreading dynamics based on complex networks have received widespread attention these years due to the COVID-19 epidemic, which are conducive to corresponding prevention policies. As for the COVID-19 epidemic itself, the latent time

No abstract

CONCLUSION: This study revealed the critical role that social connectedness plays in promoting resilience and enhancing motivation in return to play during extremely challenging circumstances. When the social outlet is absent, enhancing resilience

CONCLUSIONS: Although the prespecified primary, secondary and exploratory efficacy endpoints, including RFF through day 28, change from baseline SaO2/FiO2 ratio on day 7, and 28-day mortality rate, were not met, nezulcitinib was generally well

This case study describes the development and implementation of a governance structure that prioritised First Nations peoples in a local public health Incident Command System activated for the COVID-19 pandemic response in New South Wales, Australia

BACKGROUND: Older adults (aged ≥60 years) were prioritised for COVID-19 booster vaccination due to severe outcome risk, but the risk for this group is also affected by previous SARS-CoV-2 infection and vaccination. We estimated vaccine effectiveness

CONCLUSION: Screening of potential biomarkers and therapeutic targets sheds new light on the pathogenesis of long COVID-associated inflammatory cardiomyopathy as well as potential therapeutic approaches. Further clinical studies are needed to explore